Connect with us

Psilocybin

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Cybin Inc. (NEO:CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the…

Published

on

Cybin Inc. (NEO:CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA.

“It is exciting to be part of this year’s SFN meeting and showcase CYB003 amongst leading scientists and academics in the area of psychedelic medicine. Our presentation at Neuroscience 2022 highlighted the findings from our CYB003 preclinical studies. Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action, and shorter duration of effect. These potential therapeutic benefits could result in reduced time and resource burden on the healthcare system and potentially improved scalability and accessibility of treatment.”

Geoff Varty, Ph.D., Head of Research & Development at Cybin

Poster Details:

Title: Pharmacological and Pharmacokinetic Profile of CYB003, A Novel, Orally Active Analog of Psilocybin for the Potential Treatment of Major Depressive Disorder

Authors: Geoffrey Varty, Michael Morgan, Joan Krakowsky, Clinton Canal, Tina Mueller, Amy Reichelt, Ken Avery, Pradip Pathare, Joshua Hartsel, Alex Nivorozhkin, Michael Palfreyman

Poster Session: Treatment and Drug Discovery for Mood Disorders. Presentation Number: 147.04

About CYB003

CYB003 is derived from psilocybin, which is part of a family of molecules called indolamines that include more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 is currently being evaluated in a Phase 1/2a clinical trial for the treatment of major depressive disorder.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Read More

Trending